Navigation Links
Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
Date:2/4/2016

LONDON, Feb. 4, 2016 /PRNewswire/ -- Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth

Summary

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

Scope

Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.
- What factors are driving the market growth?
- How can the factors limiting growth be overcome?
There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
- What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
- How does the composition of the pipeline compare with that of the existing market?
Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
- How will this affect their revenues in this period?
- How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?
The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.
- What is driving this continued market dominance?
- Who will the new market players be?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
- Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals
Download the full report: https://www.reportbuyer.com/product/3596608/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Viral Partnering Deal Trends, Players and Financials Analysis Report 2016
2. Global Breast Pumps Market Assessment & Forecast: 2015 - 2019
3. Global Life Science Microscopy Devices Market Assessment & Forecast: 2015 - 2019
4. Haemophilus influenzae Infections Global Clinical Trials Review, H2, 2015
5. Atomic Spectroscopy Market by Technology & by Application - Analysis & Global Forecast to 2020
6. Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
7. Global Blood Glucose Testing and Diabetes Management Report 2015
8. HeartWare Presentation At The Leerink Partners 5th Annual Global Healthcare Conference To Be Webcast
9. ARMO BioSciences to Present at the Leerink Partners Global Healthcare Conference
10. Medical Ceramics Market by Material, by Application, and by Region - Global Forecast to 2020
11. Luminex Corporation To Present At 2016 Leerink Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2019)... ... June 15, 2019 , ... Lycotec Ltd, a ... clinical study on its new prebiotic, LycoBiotic™, which is 1,000 – 4,000 stronger ... formulations, which were based on a proprietary composition of GA lycopene, specially developed ...
(Date:6/14/2019)... ... June 14, 2019 , ... ... a forecasting and analytics platform that helps Life Sciences Manufacturers accurately project ... for Life Sciences business leaders: accurate, automated forecasting of rebates and discounts ...
(Date:6/13/2019)... ... ... Alliance Cost Containment, LLC (ACC) secured $5.8M in savings over ... in savings is in addition to $17.6M saved over the course of a 5-year ... Q4 2019, the client increased their Fortune 500 status in the healthcare industry. The ...
Breaking Medicine Technology:
(Date:6/12/2019)... ... , ... In September of 2018, NVNA and Hospice (NVNA) partnered with Health ... Following its full-scale launch in March, NVNA has expanded its program with HRS to ... NVNA has achieved an average all-cause hospital readmissions rate of 7.3% and has seen ...
(Date:6/12/2019)... ... June 12, 2019 , ... We are excited to announce ... Pinnacle, a top-rated healthcare system, providing cutting-edge fertility treatment to patients in Central ... premier insurance plans because of our commitment to evidence-based medicine and best practices,” ...
(Date:6/12/2019)... ... June 12, 2019 , ... Millions of people across ... from participating in education or the workforce, and even from accessing health care. ... as a human right and address communication disability in ways that foster inclusion ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... has announced a new Revenue Cycle Management (RCM) service at the company’s annual ... part of the company’s growing HCHB Services Suite, a collection of technology-enabled services ...
(Date:6/11/2019)... HOUSTON (PRWEB) , ... June 11, 2019 , ... CareSet ... Journal’s 40 under 40. Patel helped guide CareSet through the TMCx Accelerator startup program ... company of six employees two years ago has grown into a company of 18 ...
Breaking Medicine News(10 mins):